DT Investment Partners’s BioMarin Pharmaceuticals BMRN Stock Holding History

DT Investment Partners’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$9.61K	Hold	168	–	–	﹤0.01%	393
2026 Q1	$9.49K	Hold	168	–	–	﹤0.01%	392
2025 Q4	$9.98K	Hold	168	–	–	﹤0.01%	415
2025 Q3	$9.1K	Hold	168	–	–	﹤0.01%	417
2025 Q2	$9.23K	Hold	168	–	–	﹤0.01%	413
2025 Q1	$11.9K	Hold	168	–	–	﹤0.01%	378
2024 Q4	$11K	Sell	168 -55	-25%	-$3.68K	﹤0.01%	399
2024 Q3	$15.7K	Buy	223 +55	+33%	+$4.6K	﹤0.01%	389
2024 Q2	$13.8K	Sell	168 -63	-27%	-$5.25K	﹤0.01%	349
2024 Q1	$20.2K	Hold	231	–	–	﹤0.01%	286
2023 Q4	$20.7K	Hold	231	–	–	﹤0.01%	275
2023 Q3	$20.4K	Hold	231	–	–	﹤0.01%	259
2023 Q2	$20.6K	Hold	231	–	–	﹤0.01%	265
2023 Q1	$22.4K	Hold	231	–	–	﹤0.01%	258
2022 Q4	$23.9K	Hold	231	–	–	﹤0.01%	251
2022 Q3	$20K	Buy	+231	New	+$20.6K	﹤0.01%	250

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

DT Investment Partners's BMRN Position: Q2 2026 in Review

DT Investment Partners held its BioMarin Pharmaceuticals (BMRN) position steady in Q2 2026 at 168 shares worth $9.61K. The position accounts for ﹤0.01% of the portfolio, ranked #393.

DT Investment Partners first reported a position in BMRN in Q3 2022 and has held it in 16 quarters since. The position peaked at $23.9K in Q4 2022. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

DT Investment Partners held 168 shares of BioMarin Pharmaceuticals worth $9.61K as of Q2 2026.
DT Investment Partners left its BioMarin Pharmaceuticals share count unchanged in Q2 2026.
BioMarin Pharmaceuticals made up ﹤0.01% of DT Investment Partners's portfolio in Q2 2026, its #393 holding.
DT Investment Partners first reported a position in BioMarin Pharmaceuticals in Q3 2022 and has held it in 16 quarters since.
DT Investment Partners's BioMarin Pharmaceuticals position peaked at $23.9K in Q4 2022.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on DT Investment Partners's 13F filing for Q2 2026, filed 27 Jul 2026.